Abstract Background About 3%–5% of non‐small cell lung cancer (NSCLC) presents
positive anaplastic lymphoma kinase (ALK). Recently, several target agents have been …

ABSTRACT INTRODUCTION Anaplastic Lymphoma Kinase (ALK)-rearranged advanced
non-small cell lung cancer (aNSCLC) represents 4% of all NSCLC, and multiple ALK …

Among the many reports published on strategies applicable to synthesizing pyrazolines and
its analogs, The 1, 3-dipolar cycloaddition offers a remarkably wide range of utility. Many 1, 3 …

Lung cancer is among the leading causes of death related to cancer globally, with NSCLC
(non-small cell lung cancer) accounting for about 85% of all cases. NSCLC is characterized …

The number of targeted therapies licenced for non-small cell lung cancer (NSCLC) has
increased substantially in recent years, resulting in a major increase in demand for genomic …

In early oncology clinical trials there is often limited data for biomarkers and their association
with response to treatment. Thus, it is challenging to decide whether a biomarker should be …

Objectives Non-small cell lung cancer (NSCLC) patients with pleural dissemination are
generally contraindicated for surgery. This study aimed to investigate the survival benefits of …

Background Despite the growing use of next-generation sequencing (NGS) in the
management of advanced non-small-cell lung cancer (NSCLC), there is little evidence that …

Background In recent years, groundbreaking advancements in lung cancer research have
paved the way for innovative treatments directly targeting KRAS mutations, which have long …

During the last two decades, the field of targeted therapy against oncogene-driven tumors
has witnessed meaningful and accelerated advancements. Ever since the discovery of ALK …